Entera Bio (ENTX) Return on Capital Employed (2022 - 2026)
Entera Bio (ENTX) posted quarterly Return on Capital Employed of 96.79% for Q1 2026, down 2383.0% year-on-year from 4.24% in Q1 2025, and down 21.04% on a QoQ basis from 79.96% in Q4 2025.
Entera Bio (ENTX) Return on Capital Employed (2022 - 2026) Analysis & Trends
Entera Bio (ENTX) has reported Return on Capital Employed for 5 consecutive years, with 96.79% the latest figure, recorded in Q1 2026.
- Quarterly Return on Capital Employed fell 2383.0% year-over-year to 96.79% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 96.79% (down 2383.0% YoY) and the FY2025 annual result came in at 109.92%, down 797.0% from the prior year.
- Return on Capital Employed declined to 96.79% in Q1 2026 per ENTX's latest filing, from 79.96% in the prior quarter.
- Over the last five years, Return on Capital Employed for ENTX reached as high as 56.53% in Q2 2025 and fell as low as 133.67% in Q3 2023.
- A 5-year average of 93.06% and a median of 96.79% in 2026 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 4660 bps — and 2025, when it surged 5464 bps.
- Year by year, Return on Capital Employed stood at 100.19% in 2022, then advanced by 2 bps to 97.98% in 2023, then slumped by 33 bps to 130.18% in 2024, then jumped by 39 bps to 79.96% in 2025, then declined by 21 bps to 96.79% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 96.79%, 79.96%, and 64.25% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Entera Bio | 186.78 Mn | 182.64 Mn | - | -96.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -96.79% |
| Dec 31, 2025 | -79.96% |
| Sep 30, 2025 | -64.25% |
| Jun 30, 2025 | -56.53% |
| Mar 31, 2025 | -72.96% |
| Dec 31, 2024 | -130.18% |
| Sep 30, 2024 | -118.89% |
| Jun 30, 2024 | -97.38% |
| Mar 31, 2024 | -88.46% |
| Dec 31, 2023 | -97.98% |
| Sep 30, 2023 | -133.67% |
| Jun 30, 2023 | -114.35% |
| Mar 31, 2023 | -104.80% |
| Dec 31, 2022 | -100.19% |
| Sep 30, 2022 | -87.07% |
| Jun 30, 2022 | -75.72% |
| Mar 31, 2022 | -62.86% |